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Abstract
Signal transduction with the diatomic radical nitric oxide (NO) is involved in a number of important physiological
processes, including smooth muscle relaxation and neurotransmission. Soluble guanylate cyclase (sGC), a heterodimeric
enzyme that converts guanosine triphosphate to cyclic guanosine monophosphate, is a critical component of this signaling
pathway. sGC is a hemoprotein; it is through the specific interaction of NO with the sGC heme that sGC is activated. Over
the last decade, much has been learned about the unique heme environment of sGC and its interaction with ligands like NO
and carbon monoxide. This review will focus on the role of sGC in signaling, its relationship to the other nucleotide cyclases,
and on what is known about sGC genetics, heme environment and catalysis. The latest understanding in regard to sGC will
be incorporated to build a model of sGC structure, activation, catalytic mechanism and deactivation. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Soluble guanylate1 cyclase (sGC) is the only con-
clusively proven receptor for nitric oxide (cNO), a
signaling agent produced by the enzyme nitric oxide
synthase (NOS) from the amino acid L-arginine. As
shown in Fig. 1, sGC catalyzes the conversion of
guanosine 5P-triphosphate (GTP) to cyclic guanosine
3P,5P-monophosphate (cGMP). Because it is one of
two enzymes (the other is the membrane-bound pep-
tide-receptor guanylate cyclase) that produce cGMP,
and because it is the only de¢nitive receptor for cNO,
sGC is intimately involved in many signal transduc-
tion pathways, most notably in the cardiovascular
system (e.g., in the regulation of vascular tone and
platelet function) and in the nervous system (e.g. in
neurotransmission and, possibly, long-term potentia-
tion and depression). Soluble guanylate cyclase is a
heterodimeric protein composed of K and L subunits;
in addition, it is a hemoprotein (see Fig. 2). cNO
binds to the sGC heme; this binding event activates
the enzyme. The activation of sGC and the subse-
quent rise in cGMP concentration are what allow
sGC to transmit an cNO signal to the downstream
elements of the signaling cascade-cGMP-dependent
protein kinase, cGMP-gated cation channels and
cGMP-regulated phosphodiesterase. As will be de-
scribed below, nearly 30 years of study of sGC
have given us an outline of sGC structure and func-
tion; however, many facets of sGC structure and
function, especially at the molecular level, remain
to be discovered.
2. Historical perspective
Although both sGC and its product, cGMP, were
identi¢ed in the 1960s, it has been only within the
last 10 years that the complete outline of the cNO/
cGMP signaling pathway has been understood. After
the discovery of cAMP in 1958 [1] and the initial
elucidation of its role in physiology (for early reviews
see [2,3]), the search for other physiologically rele-
vant cyclic nucleotides began. In 1963, cGMP was
detected in the urine of rats [4]; several years later,
guanylate cyclase was found in mammalian tissues
[5^9]. In 1977, cNO 9 both as cNO gas and as cNO
released from vasodilators like nitroglycerin and
nitroprusside 9 was shown to activate guanylate
cyclase [10^13]. At that point, though, cNO was
unknown in biological systems, except when exoge-
nously supplied by drugs like nitroglycerin, so it was
assumed that cNO activation of sGC was a non-
physiological, if useful, phenomenon.
The story soon became clear, however. In 1980,
Furchgott et al. were able to demonstrate the exis-
tence of a substance produced by the endothelium
that was required to mediate relaxation of blood
1 Although we prefer ‘guanylate’ cyclase (as does the Index
Medicus and the Oxford Dictionary of Biochemistry and Molec-
ular Biology), ‘guanylyl’ cyclase is also used. Neither of the com-
mon names for this enzyme is technically correct: ‘guanylate’
refers to the anion of guanylic acid (guanosine monophosphate)
and ‘guanylyl’ refers to the acyl group derived from guanylic
acid.
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vessels [14]. They designated this substance endothe-
lium-derived relaxing factor (EDRF). In 1986, Ignar-
ro and Furchgott independently suggested that
EDRF was cNO (reviewed in [15]); the next year, it
was demonstrated that this was the case [16,17]. At
the same time, our laboratory and others were un-
raveling the story of nitrite (NO32 ) and nitrate (NO
3
3 )
production in mammals. After initial observations by
Tannenbaum and coworkers that mammals produce
NO33 and that NO
3
3 synthesis is increased following
immune stimulation [18^20], it was shown that NO32
and NO33 were produced by immunostimulated mac-
rophages from the amino acid arginine (reviewed in
[21,22]). Shortly thereafter, our laboratory and
others demonstrated that a soluble enzyme in murine
macrophages, later puri¢ed and named nitric oxide
synthase, was producing cNO from the amino acid
arginine [23^25]. At this point, the major compo-
nents of the cNO/cGMP signaling pathway had
been identi¢ed: nitric oxide synthase produces cNO,
which activates soluble guanylate cyclase, leading to
a subsequent increase in the concentration of cGMP.
3. Signaling with the cNO/cGMP pathway
Since the initial elucidation of the cNO/cGMP sys-
tem, many good examples of signal transduction by
this system have come to light, some better charac-
terized than others. They include: smooth muscle
relaxation and blood pressure regulation [26]; plate-
let aggregation and disaggregation [27]; and neuro-
transmission both peripherally, in non-adrenergic,
non-cholinergic (NANC) nerves [26], and centrally,
in the processes of long term potentiation and de-
pression [28]. Understanding the cNO/cGMP path-
way, however, requires an understanding of cNO’s
role as a signaling agent, the alternative targets for
cNO, the alternative activators of sGC and, natu-
rally, the targets for cGMP.
It was initially a surprise that cNO was produced
physiologically: prior to the demonstration of cNO
synthesis by nitric oxide synthase, the biological rele-
vance of cNO was as a pollutant; for example, as a
component of automobile exhaust. Given the phys-
ical properties of cNO, however, it is now clear that
cNO is uniquely well suited to its role as a signaling
agent. Because it is small and carries no charge, cNO
di¡uses freely across cell membranes, obviating the
need for a transport system. cNO is relatively unreac-
tive for a radical species, so that it can di¡use from a
cell in which it is produced to neighboring cells with-
out being destroyed before it reaches its target. Be-
cause cNO is oxidized to NO32 and NO
3
3 under phys-
iological conditions, no separate mechanism for its
destruction is required [29^31]; however, at low con-
centrations of cNO and in the absence of proteins
and metals which contribute to its destruction, the
decomposition of cNO will be slow [29]. Most impor-
tantly, the electronic structure of cNO makes it an
excellent ligand for heme, allowing it to bind to the
sGC heme at a low, non-toxic concentration.
The one well-de¢ned target for cNO, of course, is
sGC; however, several paths for cNO signal trans-
duction which do not rely on the production of
cGMP by sGC have been proposed, though they
are less clearly de¢ned than the cNO/cGMP pathway.
First, cNO was shown to inhibit mitochondrial cyto-
chrome oxidase at concentrations of cNO found
physiologically [32,33]. Second, cNO was reported
to activate calcium-dependent potassium channels
in vascular smooth muscle directly, though it is pos-
sible that this only happens with levels of cNO higher
than typically seen in vivo [34]. Third, cNO was
shown to inhibit activation of NF-UB [35,36].
Fourth, cNO was found to activate G-proteins
(such as protooncogene p21ras) by enhancing the
rate of nucleotide exchange, leading to an increase
in the GTP-bound form. In fact, a p21ras cysteine
residue (C118) was shown to be S-nitrosylated in the
presence of cNO [37^39]. Fifth, caspase, a cysteine
protease involved in apoptosis, was shown to be in-
hibited by S-nitrosylation of its active-site cysteine
[40]. Finally, both hemoglobin and the cardiac calci-
um release channel (i.e., the ryanodine receptor) were
shown to be S-nitrosylated in vivo; moreover, this
change resulted in a modi¢cation of their function
[41^43]. As these alternative cNO targets become bet-
ter de¢ned, it will be important to ensure that they
are physiologically relevant. cNO, especially at high
concentration, can react with O2 through a series of
reactions to form N2O3, which is a potent nitrosating
agent reacting capable of reacting with nucleophiles
such as the sulfur of cysteine residues. As a result, in
vitro experiments with high cNO concentrations may
lead to higher than normal levels of S-nitrosocysteine
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formation. Therefore, while there is no doubt that S-
nitrosylation occurs in vivo, we believe its physiolog-
ical signi¢cance will not be established until two ob-
servations are made: ¢rst, that S-nitrosylation 9 at
in vivo levels of cNO 9 modi¢es the function of
target proteins and, second, that in vivo concentra-
tions of S-nitrosylated proteins can elicit a physio-
logical response.
In addition to other targets for cNO, there are
other potential physiological activators of sGC.
These fall into two categories 9 non-cNO nitroge-
nous compounds and carbon monoxide (CO).
Although most investigators are now convinced
that cNO itself is the signaling agent which activates
sGC, there are still some who believe that there are
other nitrogenous products (not cNO) which acti-
vates sGC. Many alternatives have been proposed,
such as nitrosothiols. It is not clear, however, that
these agents are present in high enough concentra-
tion in vivo to perform any signi¢cant signaling func-
tion. Likewise, it has been hypothesized that CO,
which binds to the sGC heme and weakly activates
the enzyme, may act as a signaling agent [44^46]. In
contrast to cNO, which activates sGC approx. 400-
fold, CO only activates known isoforms of sGC ap-
prox. 5-fold [47]. Additionally, CO activation re-
quires saturating concentrations of CO, a clearly
non-physiological alternative. Although CO is pro-
duced by the enzyme heme oxygenase during the
breakdown of heme, it is di⁄cult to imagine that
cells can provide an adequate supply of free heme
(which is toxic to cells) for signaling with CO. In
the absence of a more CO-sensitive sGC isoform or
a mechanism to increase the response of sGC to CO,
we will have to reserve judgment on this potential
pathway. Such a mechanism may have been found,
however. It has been shown recently that CO and the
synthetic compound YC-1 ([48]; see Fig. 4 for the
structure) synergistically activate sGC to levels sim-
ilar that of the cNO-stimulated enzyme [49,50]. If a
physiological counterpart for YC-1 is identi¢ed, this
could be a mechanism by which CO could act as a
signaling agent.
Regardless of the species that activates sGC, all
signal transduction through sGC (and pGC as well)
takes place through an increased concentration of
cGMP. Cyclic GMP, like cAMP, is a second messen-
ger; as such, it requires target proteins to have its
e¡ect. Moreover, the diversity of targets allows
cGMP to have wide-ranging e¡ects that can di¡er
by cell and tissue type. There are three known targets
for cGMP which mediate the transmission of the
cNO/cGMP pathway signal downstream from guany-
late cyclase: cGMP-dependent protein kinase [51],
cGMP-regulated phosphodiesterase [52,53] and
cGMP-gated ion channels [54]. The ¢rst of these,
cGMP-dependent protein kinase, phosphorylates tar-
get proteins in response to an increase in cGMP con-
centration. For example, in smooth muscle cells,
cGMP-dependent protein kinase phosphorylates the
inositol 1,4,5-triphosphate receptor, leading to a de-
crease in Ca2 concentration and, ultimately, smooth
muscle relaxation. The second, cyclic nucleotide
phosphodiesterase, catalyzes the hydrolysis of the
3P-phosphodiester bond of cAMP and cGMP to yield
AMP and GMP, respectively. Of the seven known
families, three (PDE2, PDE5 and PDE6) are allos-
terically regulated by cGMP and one (PDE3) is in-
hibited by the binding of cGMP in its substrate site.
Phosphodiesterases allow crosstalk between cGMP
and cAMP signaling pathways because they cause
the concentration of one cyclic nucleotide to in£u-
ence the degradation of the other. The third, cyclic
nucleotide-gated ion channels, are non-speci¢c cation
channels found in a variety of tissues. Most notably,
these channels are found in the retina and in olfac-
tory epithelium where they are involved, respectively,
in visual phototransduction and in olfaction.
4. The nucleotide cyclase family: sGC, pGC and AC
Just as sGC is a component of the larger cNO/
cGMP signaling pathway, so is it a member of a
larger group of related enzymes: the nucleotide cy-
clases. This family of enzymes converts nucleotide
triphosphates (GTP and ATP) to cyclic nucleotide
monophosphates (cGMP and cAMP) and includes
adenylate cyclase (AC), particulate guanylate cyclase
(pGC) and soluble guanylate cyclase. As a family,
these enzymes are involved in a broad array of signal
transduction pathways mediated by the cyclic nucleo-
tides cAMP and cGMP-vision, blood pressure regu-
lation, response to hormones and many others. An
evolutionarily conserved catalytic domain de¢nes
these three groups of enzymes as a single family; in
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other words, the genes that code for the catalytic
portions of these enzymes are derived from a com-
mon ancestor. This is unsurprising, given that they
catalyze virtually identical reactions. Moreover, be-
cause of their relatedness and similar function, in-
sights into the structure, catalytic mechanism and
possibly even regulation of one member of this fam-
ily may be generalizable to other members.
Adenylate cyclase, for example, has been studied
for nearly four decades. As a result, there is a rich
literature of ¢ndings with AC that may, because of
the similarity of AC to sGC, prove useful in under-
standing sGC. Unlike the guanylate cyclases, which
contain both receptor and catalytic functions within
the same protein, ACs are stimulated by hormone
receptors acting through heterotrimeric G-proteins
[55]. AC is an integral membrane protein and is as-
sumed to be monomeric. All of the known mamma-
lian isoforms are activated by GsK ; other activators
are isoform speci¢c [56]. AC is also activated by the
small molecule forskolin, a diterpene derivative iso-
lated from the Indian plant Coleus forskohli. Forsko-
lin was originally shown to have a variety of cardio-
vascular e¡ects [57] and was later shown to activate
AC [58]; it has served as a useful tool in the study of
AC, but no mammalian counterpart has been iden-
ti¢ed. As shown in Fig. 2, AC contains two groups
of six transmembrane helices and two intracellular
loops. The intracellular loops each contain a region
9 C1 and C2, respectively 9 now known to come
together in a head-to-tail fashion to form a function-
al catalytic domain. (Because the domain is made up
of two regions from a single polypeptide chain, it is
sometimes referred to as ‘pseudo-heterodimeric’.)
Two crystal structures of catalytic domains have, in
fact, been solved recently. The ¢rst was a structure of
a C2C2 homodimer [59], the second of a C1C2 heter-
odimer [60]; both were engineered constructs which
lacked the transmembrane domains and were, thus,
soluble. The crystal structure of C1C2 supports the
conclusion that this pseudo-heterodimeric catalytic
domain has two pseudo-symmetric binding sites:
one binds substrate, the other forskolin. In addition,
GsK binds to a site in the plane of the catalytic do-
main opposite the substrate binding site.
Particulate guanylate cyclase has also provided in-
sight into the structure and function of sGC. After
the puri¢cation of cGMP and guanylate cyclase, it
was observed that guanylate cyclase activity could be
separated into a membrane-bound (particulate) and
cytosolic (soluble) fractions. As its name implies,
particulate guanylate cyclase is the membrane-bound
Fig. 1. The guanylate cyclase reaction and cNO signal transduction.
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guanylate cyclase. In a sense, pGC is a prototypic
cell-surface receptor enzyme: it contains an extracel-
lular peptide receptor domain and an intracellular
catalytic domain separated by a single transmem-
brane domain (Fig. 2). pGC is now generally thought
to be a homodimer of subunits of approx. 120 kDa
[61]. Seven subclasses of mammalian pGC (GC-A
through GC-G) have been identi¢ed. Three of these
have known peptide ligands (GC-A, atrial natriuretic
peptide and brain natriuretic peptide; GC-B, C-type
natriuretic peptide; GC-C, the heat stable enterotox-
ins of Escherichia coli and guanylin); the rest (GC-D,
olfactory epithelium; GC-E and GC-F, retina;
GC-G lung, intestine, skeletal muscle) are so-called
‘orphan’ receptors because their activating ligands
have not been determined [55,61,62]. For the pur-
poses of understanding sGC, pGC is useful because
it helps to de¢ne the characteristics that are speci¢c
to guanylate cyclases, for example, the identity of
the amino acids which allow the di¡erent members
of the nucleotide cyclase family to distinguish GTP
from ATP [63]. Also, given the similarity of their
catalytic domains, it is possible that the general
mechanism of activation of pGC will be similar to
that of sGC.
5. Soluble guanylate cyclase genetics and isoforms
Since the original identi¢cation of sGC, a great
deal of information about sGC genetics has become
available. Thus far, a total of 12 sGC cDNAs have
been cloned from ¢ve di¡erent species (for identity
and similarity comparisons see Fig. 3). The ¢rst were
cloned on the basis of protein sequence from puri¢ed
bovine and rat K1L1 heterodimer. The cDNA se-
quences for bovine and rat L1 subunits, respectively,
were reported in 1988 [64,65], followed by the bovine
and rat K1 subunits in 1990 [66,67]. Subsequently,
K1L1 pairs were cloned from Homo sapiens (origi-
nally called K3 and L3) ([68,69], localized to chromo-
some 4q32, [70]), Drosophila melanogaster [71^73]
and the ¢sh Oryzias latipes [74]. Putative sGC se-
quences exist in the Caenorhabditis elegans genome,
but these have yet to be con¢rmed with any empiri-
cal studies beyond the sequencing itself.
Fig. 2. Schematic representation of sGC, pGC and AC. Transmembrane helices are shown in purple, the conserved sGC, pGC and
AC catalytic regions are shown in orange and the conserved NH2-terminal domains of the sGC K1 and L1 subunits are shown in
green. The sGC L1 subunit also binds prosthetic heme, which is ligated by histidine 105.
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In addition to the cloning of K1L1 pairs, the
cDNAs for two additional sGC subunits have been
cloned: L2 from rat kidney [75] and K2 from human
fetal brain ([76], localized to chromosome 11q21-q22
[77]. In transient transfection experiments, the K2
subunit has been shown to form an active hetero-
dimer with the L1 subunit [76]. Although the L2 sub-
unit has been recently reported to form an active
heterodimer with the K1 subunit in transient expres-
sion experiments [78], similar experiments in our lab-
oratory (unpublished results) and others (unpub-
lished results, see [79,80]) were unable to generate
an active heterodimer containing the L2 subunit.
Thus, the issue of the L2 subunit partner remains
to be conclusively proven. A unique feature of the
L2 subunit is that its predicted amino acid sequence
contains a COOH-terminal consensus sequence
(-CVVL) for isoprenylation/carboxyl-O-methylation
[75], but it is not known whether such a modi¢cation
exists on the mature polypeptide. Because full-length
sequences of the K2 and L2 subunits from species
other than the ones from which they were originally
isolated have yet to be identi¢ed, one might question
their signi¢cance. However, a partial sequence for
the bovine K2 has been determined [76] and a puta-
tive L2 subunit partial sequence exists in a mouse
placenta EST database (GenBank accession No.
AA023957, from the Soares mouse placenta library).
These subunits, then, may well be common to all
mammals and perhaps to other sGC-containing spe-
cies.
The potential existence of novel sGC isoforms (i.e.,
in addition to the K1L1) raises an important issue
about the distinction between sGC subunits and
Fig. 3. Sequence identity and similarity among the predicted amino acid sequences of known sGC subunits. Translated cDNA se-
quences for the indicated sGC subunits were compared using the program Gap with gap weight = 12 and length weight = 4 (Wisconsin
Package Version 9.1, Genetics Computer Group (GCG), Madison, WI, USA). The de¢nitions of the three letter species codes above
are: bov, bovine, Bos taurus ; hum, human, H. sapiens ; rat, Rattus rattus ; fsh, Medaka ¢sh O. latipes ; dro, D. melanogaster. GenBank
accession numbers for the cDNA sequences are as follows: bovine K1, X54014; human K1, X66534; rat K1, M57405; O. latipes K1,
AB000849; Drosophila K1, U27117; human K2, X63282; bovine L1, Y00770; human L1, X66533; rat L1, M22562; O. latipes L1,
AB000850; Drosophila L1, U27123; rat L2, M57507.
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sGC isoforms. Our de¢nition of an sGC isoform is a
catalytically competent heterodimer (in principle,
however, it could be a homodimer). For AC (which
exists as a monomer) and pGC (which exists as a
homodimer), the identi¢cation of di¡erent isoforms
9 with di¡erent tissue or developmental distribution,
di¡erent regulation and/or di¡erent kinetic parame-
ters 9 has been relatively simple: each distinct gene
product is a distinct isoform. For sGC, the picture is
somewhat more complicated. Given that four distinct
sGC subunits have been cloned, there are 16 possible
homodimeric and heterodimeric combinations of
sGC subunits. Each of these combinations, if shown
to exist in vivo, could be rightly called an isoform.
The only isoform, therefore, that has been shown to
exist at the protein level in animal tissues is the K1L1.
Again, as mentioned above, putative K2L1 and K1L2
isoforms have been demonstrated in transient mam-
malian expression experiments [76,78], but until these
subunits are shown to exist in vivo and, ideally, pu-
ri¢ed from tissue sources, they cannot be considered
bona ¢de sGC isoforms. Because the role (even the
existence) of sGC isoforms other than the K1L1 is
poorly understood, our discussion of sGC character-
istics will, by necessity, focus on the K1L1 isoform.
An additional curiosity about the heterodimeric
nature of sGC is the apparent requirement for co-
expression of sGC subunits. For example, sGC K1
and L1 subunits, when expressed separately in tran-
sient mammalian expression systems, have no guany-
late cyclase activity [67,73,81]. In fact, there is still no
detectable guanylate cyclase activity when the soluble
fractions from cells expressing the K1 and L1 subu-
nits individually are mixed [73,81]. Only when the K1
and L1 subunits are co-expressed (i.e., produced in
the same cell) does basal and cNO-stimulated activity
result [67,73,81]. The sGC requirement for co-expres-
sion is similar to that of bacterial luciferase, which
has been investigated extensively in the Baldwin lab-
oratory ([82], for a review of co-translational protein
folding, see [83]). It is possible that sGC, like bacte-
rial luciferase, has one subunit that can, in addition
to normal heterodimerization, form a kinetically
trapped homodimer or fold to a dimerization-incom-
petent monomer.
6. Puri¢cation from mammalian tissue and expression
systems
Although the existence of other isoforms of sGC
besides the K1L1 has been suggested by cloning and
expression experiments, only the K1L1 has been pu-
ri¢ed from mammalian tissue. In the past, a number
of di¡erent sources for sGC, including lung, liver,
and brain, were used for puri¢cations. Early puri¢-
cations (see, for example, [84,85]) produced enzyme
with little or no bound heme [86]. Because of the
high sGC content and ready availability, bovine
lung is now used as a source for puri¢cation from
mammalian tissue. The groups currently purifying
sGC from bovine lung use a variety of puri¢cation
procedures [47,87^92]. Most of the more recent pu-
ri¢cations have been modi¢ed to increase the yield of
heme-containing sGC. In addition, yields have been
increased: puri¢cation from tissue can yield up to 3^
5 mg of pure protein (S. Kim, M.A. Marletta, un-
published data; [92]).
Because isolation of sGC from bovine lung is typ-
ically arduous, there has been strong motivation for
Fig. 4. Activators and inhibitors of sGC. Shown in panel A are
compounds known to interact directly with sGC. As described
in the text, YC-1 is an activator of sGC that acts synergistically
with CO to yield activity comparable to that observed with
cNO. ODQ is a relatively potent inhibitor of the enzyme,
although the mechanism of action is not clearly established. It
has been reported to oxidize the ferrous heme moiety [124].
Shown in panel B are compounds that have been reported to
a¡ect catalytic activity. Methylene blue and LY83583 are re-
ported to inhibit the enzyme and isoliquiritigenin has been re-
ported to activate the enzyme. Studies with these compounds
have typically been carried out with crude preparations of the
enzyme and so the exact mechanism of action is not clear.
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the development of alternative sources of sGC,
namely, the development of expression systems.
Both transient and stable expression of sGC in mam-
malian expression systems using COS cells (an Afri-
can green monkey kidney cell line) and HEK293 cells
(a human embryonic kidney cell line) has successfully
produced active cyclase in several laboratories
[67,73,76,78,81]. Unfortunately, while these systems
have been useful for exploring the catalytic activity
of sGC isoforms and mutants, the low level of pro-
tein produced has made them unsuitable as sources
of puri¢ed protein. In order to take advantage of an
expression system that can generate amounts of sGC
suitable for puri¢cation, several labs (including ours)
have used expression and puri¢cation of sGC in the
baculovirus/Sf9 system [93^96]. In general, puri¢ca-
tion of sGC from baculovirus/Sf9 expression systems
is more straightforward because it requires a lower
puri¢cation factor. Obviously, the ability to express
heterodimeric sGC at high levels in E. coli would be
a tremendous boon to the ¢eld. Many laboratories
have doubtless tried to do just that and have been, to
this point, unsuccessful 9 and here we can judge
only by our own experience, given the lack of pub-
lished reports 9 because sGC tends to form insolu-
ble inclusion bodies when expressed in E. coli. To
our knowledge, the only sGC construct that has
been successfully overexpressed in E. coli is the L1
subunit heme binding region that has been expressed
and puri¢ed in our laboratory [97,98].
7. Heme environment
Although there has been some debate in the past,
it is clear now that sGC binds one protoporphyrin
IX type heme per heterodimer. The early history of
the determination that sGC is a hemoprotein is re-
viewed in [99]. After initial observations that heme
was needed to allow stimulation of sGC by cNO in
crude preparations [100,101], sGC was shown to con-
tain a prosthetic heme moiety that was important in
activation by cNO and cNO donors [85,102^104]. Be-
cause the early puri¢cations yielded sGC with heme
stoichiometries less than one (often far less than one)
[86], it was assumed that the heme stoichiometry was,
in fact, one. After the cloning of both K and L sGC
subunits and the cloning of some of the pGC iso-
forms, it became clear that the COOH-terminal por-
tion of both sGC subunits was most likely catalytic
in nature. In addition, as our laboratory noted
[47,87], the NH2-terminal portions 9 upstream
from the conserved catalytic regions 9 of both the
K and L subunits were homologous to each other
(i.e., 30% identical and 39% similar), though less ho-
mologous at the extreme NH2 terminus. This obser-
vation led us to hypothesize that both subunits might
bind heme. Initially, our heme stoichiometry deter-
mination for sGC supported that hypothesis [87];
however, recent work in our laboratory has demon-
strated that there had been an error in the quanti-
tative amino acid analysis used to determine sGC
concentration. As a result, we have de¢nitively deter-
mined the heme stoichiometry to be one heme per
heterodimer ([93]; S. Kim, P.E. Brandish, M.A. Mar-
letta, unpublished data).
The hypothesis that the sGC heme is ligated by a
histidine residue, much like the well-studied heme
proteins hemoglobin and myoglobin, is not new;
however, it has been only within the last several
years that that suspicion has been con¢rmed and
the ligand identi¢ed as histidine 105 of the L1 sub-
unit (the numbering applies to bovine, human and
rat L1). Early observations of the sGC heme Soret
(i.e., the maximal heme absorbance peak) as isolated
[102] hinted that sGC was likely to bind heme in a
way similar to deoxyhemoglobin and deoxymyoglo-
bin, namely, as a ¢ve-coordinate histidyl complex. It
was not until two relatively recent observations were
made that this picture began to become clear. First, a
mutant of sGC in which histidine 105 of the bovine
L1 subunit had been mutated to phenylalanine
(H105F) and transiently expressed in COS cells was
found to have lost stimulation by cNO and, in addi-
tion, to lack any heme absorbance [94]. Second, elec-
tronic absorption spectroscopy on pure sGC revealed
a spectrum that was entirely consistent with a histi-
dine-ligated heme, namely, a Soret peak at 431 nm
and a broad K/L band at 562 nm [47,105]. Additional
observations with electronic absorption spectroscopy
[106], magnetic circular dichroism spectroscopy [106],
resonance Raman spectroscopy (RR) [107,108] and
Fourier transform infrared spectroscopy (FTIR)
[109] con¢rmed that the heme ligand was histidine.
Subsequent observations in our laboratory de¢ni-
tively identi¢ed L1-His105 as the heme ligand: the
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NH2-terminal portion of the L1 subunit (L11ÿ385) ex-
pressed and puri¢ed from E. coli was capable of
binding heme with spectral characteristics virtually
identical to the heterodimeric enzyme [97]; mutants
of His105 did not bind heme [98]; and heme binding
to the H105G mutant could be rescued by including
imidazole during growth and puri¢cation [98].
The majority of groups studying sGC purify the
enzyme in a ¢ve-coordinate, high-spin histidyl com-
plex that resembles deoxyhemoglobin and deoxy-
myoglobin in terms of ligation, oxidation state and
spectral characteristics. Unlike hemoglobin and my-
oglobin, however, sGC has an extremely low a⁄nity
for oxygen, which fails to bind to the sGC heme even
under 100% O2 [47]. The molecular basis for this
property is still under investigation. The failure of
sGC to bind oxygen enables sGC to act as a receptor
for cNO by allowing cNO to bind directly to the
ferrous-deoxy heme; in contrast, cNO will react
with ferrous-oxy complexes (like oxyhemoglobin) to
give nitrate and ferric heme [110]. The Soret position
for sGC heme (431 nm) coupled with a broad K/L
peak at 562 nm [47,105] is consistent with ¢ve-coor-
dinate high-spin histidyl-ligated proteins and model
compounds [111]. Despite this seeming consensus,
however, there have been reports that sGC, as iso-
lated, is a mixture of ¢ve-coordinate high-spin histid-
yl heme and six-coordinate low-spin bis-histidyl
heme [95,106,108,112]. It is not clear whether heme
reconstitution, or some other di¡erence in procedure,
is the cause of these multiple populations of enzyme.
Extensive study of the sGC heme in its cNO-bound
(NO-sGC) and CO-bound (CO-sGC) forms has giv-
en us a clear picture of the characteristics of these
species. NO-sGC is a ¢ve-coordinate nitrosyl heme,
in which the Fe-His bond has been broken
[47,92,107,108,112,113]. A combination of electronic
absorption spectroscopy, electron paramagnetic res-
onance spectroscopy (EPR) and RR has been used to
show this. When CO is bound to the sGC heme, the
Fe-His bond apparently remains intact, forming a
six-coordinate heme [47,92,106,108,112]. Observa-
tions by electronic absorption spectroscopy and RR
have demonstrated this to be the case. Table 1 shows
a summary of electronic absorption spectroscopy
maxima for sGC in its as isolated, CO-bound and
cNO-bound forms; Table 2 shows RR and FTIR
vibrations for the heme ligands of these forms.
8. Catalysis
Several lines of evidence have converged to unam-
biguously de¢ne the catalytic domain of sGC: se-
quence comparisons to AC and pGC to de¢ne an
evolutionarily conserved region, site-directed muta-
genesis to produce inactive enzyme, the construction
of deletion mutants that retain catalytic function,
and the creation of mutants with altered substrate
speci¢city. The ¢rst method that was used to de¢ne
the catalytic regions of AC, pGC and sGC was align-
ment of their predicted amino acid sequences (once
the cDNA sequences became available). These align-
ments revealed a highly homologous region approx.
200 amino acids long that was common to all three
enzymes. Two regions were found in the AC se-
quence (C1 and C2), one region in pGC monomers
and one region in each half of the sGC heterodimer
(K1 and L1). Several additional pieces of evidence
showed that these regions in the K1 and L1 subunits
of sGC came together to form the catalytic domain.
First, the mutation of two aspartic acid residues in
the sGC K1 subunit each abolished catalytic activity
in co-expressed heterodimers [114]. Second, Wedel
and coworkers demonstrated that co-expressed
NH2-terminal deletion mutants of K1 (deletion of
the ¢rst 366 amino acids) and L1 (deletion of the ¢rst
305 amino acids) retained catalytic activity [115]. Fi-
nally, any remaining doubt that these regions formed
the catalytic domain was removed by the recent ¢nd-
ing that sGC can be made into an cNO-responsive
adenylate cyclase with changes to these regions
alone: by mutating one residue in the K1 subunit
and two in the L1 subunit in the putative catalytic
regions that were predicted 9 on the basis of the AC
Table 1
Peak positions and extinction coe⁄cients from electronic ab-
sorption spectroscopy of sGC
sGC form Soret L K Por-Fea
Ferrous 431 (111) 562 (12) 770 (0.2)
CO complex 423 (145) 541 (12) 567 (12)
NO complex 399 (85) 537 (11) 572 (11)
Ferric 391 (110) 511 (14) 642 (4)
Values for this table were drawn from [47,105]. Extinction coef-
¢cients (mM31 cm31) are given in parentheses.
aPor-Fe refers to the putative porphyrin to iron charge transfer
band.
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catalytic domain crystal structures 9 to be important
in nucleotide base binding [59,60], Sunahara and
coworkers were able to change the nucleotide specif-
icity of sGC [116].
Many aspects of the catalytic mechanism of sGC
are poorly understood. The type of reaction cata-
lyzed by sGC 9 the attack of an activated hydroxyl
on the K-phosphate of a nucleotide triphosphate 9 is
a common one. This is, for example, the same reac-
tion catalyzed in the polymerization of deoxynucleo-
tide triphosphates in the synthesis of DNA; however,
in the case of DNA it is an intermolecular attack of
the 3P-hydroxyl on an K-phosphate. In fact, after
publication of the AC C2C2 structure, it was sug-
gested that AC catalytic domain contains a fold sim-
ilar to the ‘palm’ domain in prokaryotic DNA poly-
merase I [117]. It is possible that some of the features
of the DNA polymerase mechanism will hold true
for the nucleotide cyclases. Thus, the outline of the
reaction is clear: the 3P-hydroxyl is activated in some
way to become more nucleophilic and attacks the K-
phosphate, causing the release of the L- and Q-phos-
phates as inorganic pyrophosphate. What is not clear
is how the 3P-hydroxyl is activated, whether pyro-
phosphate release is concerted or proceeds through
a pentavalent phosphorous transition state and what
role divalent metal cations play in the mechanism.
Despite these questions, however, some possibilities
for the sGC mechanism have been eliminated. For
example, the displacement of PPi by the 3P-hydroxyl
of GTP has been shown to occur with inversion of
stereochemistry, which indicates that the reaction
proceeds by a single displacement reaction [118].
9. Model of sGC structure and function
In order to synthesize some of the latest sGC de-
velopments into a model 9 albeit a working model
9 we have divided sGC enzymology into four sub-
areas that represent what are, in our view, the most
important open questions: structure, activation, cat-
alytic mechanism and deactivation.
No X-ray crystal structure of sGC or of any sGC
domain has been solved; as a result, any model of
sGC structure must draw heavily on related proteins:
The high degree of homology (approx. 30% identity
and 40% similarity) between the catalytic domain of
AC and the catalytic domain of sGC, in addition to
their almost identical catalytic function, suggests that
these catalytic domains are descended from a com-
mon ancestor and, as such, are likely to share a
common three-dimensional fold. In fact, the Hurley
group has used the AC catalytic domain structure
determined in his laboratory to create a homology
model of the catalytic domain of sGC [63]. Such
models have been used to correctly predict the amino
acid residues that control the substrate speci¢city of
both ACs and GCs. For example, the substrate spe-
ci¢city of retinal guanylate cyclase (a pGC) was
changed from GTP to ATP [119], sGC was con-
verted into an cNO-activated AC and AC was con-
verted into a non-speci¢c (but still GsK-activated)
purine nucleotide cyclase [116]. As a result, the
X-ray crystal structures of the AC C1C2 heterodimer
[60] and C2C2 homodimer [59] appear to be excellent
models for the sGC catalytic domain. We would con-
cur, then, with the prediction made by others [63],
that the COOH-terminal portions of the K and L
sGC subunits form a head-to-tail catalytic domain.
If the pseudo-heterodimeric AC catalytic domain is
any guide, sGC may well have only one substrate-
binding site.
As for the rest of the protein, the lack of direct
evidence (even by analogy) makes it more di⁄cult to
choose among the possibilities; still, there are ¢nd-
ings upon which we can continue to build the model.
The homology between the K and L subunits of sGC
(33% identity and 42% similarity overall, although
Table 2
Resonance Raman and FTIR vibrations for sGC heme ligands
sGC form cm31 Description
Ferrous
X(Fe-His) 204 Fe-His stretch
CO complex
X(Fe-CO) 472 Fe-CO stretch
N(Fe-C-O) 562 Fe-C-O bending
X(C-O) 1987 C-O stretch
NO complex
X(Fe-NO) 525 Fe-NO stretch
X(N-O) 1677 N-O stretch
The values in this table were drawn from [107,109]. Similar val-
ues have been reported by other laboratories [91,92,108,112] ;
some di¡erences have been reported for reconstituted sGC
[91,108,112].
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higher in the COOH-terminal catalytic region than in
the NH2-terminal regulatory region) suggests that
the fold of the two subunits may be pseudo-symmet-
rical. The K and L subunits of sGC have a predicted
amphipathic helical region just NH2-terminal to the
predicted catalytic domain. These helices may be
evolutionarily related to the predicted amphipathic
helices NH2-terminal to the catalytic region of
pGC, which have been demonstrated to mediate di-
merization [120]. This conclusion is supported by the
homodimerization of the L11ÿ385 [97] and by the di-
merization of K1 and L1 subunit NH2-terminal dele-
tion mutants [115], which retain the putative dimeri-
zation helices. The conformational change which
shifts the AC catalytic domain to its active state
upon binding of GsK may be similar to the confor-
mational change which shifts the sGC catalytic do-
main to its active state when cNO binds to the sGC
heme. It is possible, then, that the sGC heme domain
(the NH2-terminal portion of the L subunit) abuts
the catalytic domain in the same way that GsK abuts
the AC catalytic domain [60]. This would put both
the K and L subunit NH2-terminal domains in the
plane of the catalytic domain (which is roughly
disk-shaped) 9 the heme domain opposite the sub-
strate site (in the same way GsK is opposite the AC
substrate site) and the K subunit NH2-terminal por-
tion next to the substrate site (opposite the site anal-
ogous to where forskolin binds in the AC structure).
Our model of sGC activation by cNO does not
di¡er substantially from the following simpli¢ed pic-
ture. Binding of cNO to the sGC heme severs the
bond between the heme Fe and the ligating histidine,
presumably puckers the heme toward the distal nitro-
syl ligand and, through some combination of
changes in heme geometry, causes a conformational
change that activates the enzyme. Recent work, how-
ever, has re¢ned our view of the heme environment
of sGC in a way that allows us to re¢ne our working
model of activation. As mentioned above, YC-1 is an
activator of sGC that has the interesting property of
synergistically activating sGC in the presence of CO
(see Fig. 4 for the structure of YC-1 and other sGC
activators and inhibitors). Electronic absorption
spectroscopy studies have shown that sGC activated
by YC-1 and CO has a six-coordinate heme, even
though its level of activity is similar to the cNO-acti-
vated enzyme [49,121]. Therefore, the breaking of the
Fe-His bond which occurs with cNO binding may be
correlated with the molecular event that brings about
activation, but may not directly cause it. In other
words, it is possible that the breaking of the Fe-His
bond can be eliminated as a step in the activation of
sGC. There may be, then, some other e¡ect of cNO
binding to the heme that leads to activation. We are
currently pursuing this possibility in our laboratory.
Our model of the sGC catalytic mechanism is
based largely on proteins that catalyze similar reac-
tions. In addition to this, we have incorporated what
is known about the nucleotide cyclase catalytic mech-
anisms through crystal structures and mutational
studies. The active site functions/characteristics that
need to be elucidated are as follows: the number of
substrate binding sites; the number of Mg2 ions
participating in substrate binding and/or catalysis;
the amino acid residues important for substrate bind-
ing; the amino acid residues involved in Mg2 bind-
ing; and the amino acid residues involved in the
catalytic mechanism (e.g., activation of the 3P-OH
and transition-state stabilization). There are almost
certainly no more than two substrate-binding sites in
sGC; given that the catalytic domain of sGC, like
that of AC, is made up of homologous but non-iden-
tical components, we hypothesize that there is only
one substrate-binding site, as in AC. This hypothesis
also ¢ts in well with the obvious asymmetry of the
sGC regulatory region: the L1 subunit binds heme,
the K1 does not. As for important residues, the mu-
tation of rat K1D513 and K1D529 each abolished
catalytic activity when transiently expressed with
wild-type L1 subunit [114], but it is di⁄cult to pin-
point the role that these residues may be playing
without further study.
The ¢nal component of our model of sGC struc-
ture and function is the question of deactivation,
which remains an open question because of the fol-
lowing observation: the deactivation of sGC in or-
gan bath studies has suggested that the half-life of
sGC activation is on the order of minutes [17],
whereas the half-lives of most nitrosyl-heme com-
plexes are longer. Two hypotheses have been ad-
vanced to explain this discrepancy. First, the sGC
heme may simply have di¡erent characteristics that
allow cNO to dissociate more rapidly. Second, there
may be some extrinsic factor 9 a small molecule or
protein 9 which assists in the deactivation either by
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directly interacting with the ferrous-nitrosyl heme or
via an allosteric e¡ect that increases the rate of cNO
dissociation from the heme. Studies of the sGC
heme, for example, showed that its properties were
di¡erent from most histidine-ligated heme proteins
and model compounds: the half-life (extrapolated
to 37‡C) for cNO dissociation was on the order of
2 min [122]. Recent work in our laboratory has
shown that thiol compounds like glutathione, at con-
centrations similar to that found in vivo, increase the
rate of cNO release from the heme [93]. Compounds
that trap cNO, like oxyhemoglobin, also increase the
rate of cNO release from the sGC heme [93,122].
There has been a report that the presence of Mg2-
GTP increases the rate of deactivation [123]; how-
ever, we have found that a precipitate which forms
under these conditions complicates the determination
of such rates [93]. We believe, therefore, that the
relatively fast cNO o¡-rate for the sGC heme [122]
and contribution of thiol compounds like glutathione
account for most, if not all, of the in vivo rate of
deactivation.
10. Conclusion
We have attempted in this review to provide some
insight into the structure and function of soluble
guanylate cyclase. In doing so, we have placed sGC
in its larger context by discussing the history of the
sGC ¢eld, the physiological importance of the cNO/
cGMP pathway and its components, and the nucleo-
tide cyclase family to which sGC belongs. We have
delved into the current understanding of sGC by
discussing what is known about sGC isoforms, ex-
pression and puri¢cation, heme environment and cat-
alysis. And ¢nally, we have presented a working
model of sGC structure, activation, catalytic mecha-
nism and deactivation. Naturally, a great deal of
work remains to be done to complete our under-
standing of sGC. Two important milestones in
achieving that progress will be the identi¢cation
and characterization of sGC subunits and isoforms
from several species and the development of an sGC
expression system capable of producing large quanti-
ties of the heterodimeric enzyme. With or without
these breakthroughs, the most pressing problems to
address for sGC are: (1) determining the structure,
(2) understanding the catalytic mechanism and (3)
piecing together the molecular details of activation
and deactivation. As these questions are answered,
a complete view of sGC structure and function will
emerge.
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